Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
PLoS One ; 7(1): e30680, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22292016

RESUMO

Ephrin-B2 is predominately expressed in endothelium of arterial origin, involved in developmental angiogenesis and neovasculature formation through its interaction with EphB4. Despite its importance in physiology and pathological conditions, it has been challenging to produce monoclonal antibodies against ephrin-B2 due to its high conservation in sequence throughout human and rodents. Using a novel approach for antibody selection by panning a phage library of human antibody against antigens displayed in yeast, we have isolated high affinity antibodies against ephrin-B2. The function of one high affinity binder (named as 'EC8') was manifested in its ability to inhibit ephrin-B2 interaction with EphB4, to cross-react with murine ephrin-B2, and to induce internalization into ephrin-B2 expressing cells. EC8 was also compatible with immunoprecipitation and detection of ephrin-B2 expression in the tissue after standard chemical fixation procedure. Consistent with previous reports on ephrin-B2 induction in some epithelial tumors and tumor-associated vasculatures, EC8 specifically detected ephrin-B2 in tumors as well as the vasculature within and outside of the tumors. We envision that monoclonal antibody developed in this study may be used as a reagent to probe ephrin-B2 distribution in normal as well as in pathological conditions and to antagonize ephrin-B2 interaction with EphB4 for basic science and therapeutic applications.


Assuntos
Anticorpos Monoclonais/isolamento & purificação , Antígenos/imunologia , Sequência Conservada/imunologia , Efrina-B2/imunologia , Ensaios de Triagem em Larga Escala/métodos , Biblioteca de Peptídeos , Leveduras/metabolismo , Sequência de Aminoácidos , Animais , Anticorpos Monoclonais/metabolismo , Anticorpos Monoclonais/uso terapêutico , Antígenos/química , Células CHO , Células Cultivadas , Cricetinae , Cricetulus , Efrina-B2/antagonistas & inibidores , Efrina-B2/química , Efrina-B2/metabolismo , Células HCT116 , Células HEK293 , Humanos , Camundongos , Camundongos Nus , Modelos Biológicos , Dados de Sequência Molecular , Ligação Proteica , Receptor EphB4/metabolismo , Homologia de Sequência de Aminoácidos , Ensaios Antitumorais Modelo de Xenoenxerto , Leveduras/química , Leveduras/imunologia
4.
Proc Natl Acad Sci U S A ; 108(2): 704-9, 2011 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-21187395

RESUMO

Mutational inactivation of the RB1 tumor suppressor gene initiates retinoblastoma and other human cancers. RB1 protein (pRb) restrains cell proliferation by binding E2f transcription factors and repressing the expression of cell cycle target genes. It is presumed that loss of pRb/E2f interaction accounts for tumor initiation, but this has not been directly tested. RB1 mutation is a late event in other human cancers, suggesting a role in tumor progression as well as initiation. It is currently unknown whether RB1 mutation drives tumor progression and, if so, whether loss of pRb/E2f interaction is responsible. We have characterized tumorigenesis in mice expressing a mutant pRb that is specifically deficient in binding E2f. In endocrine tissue, the mutant pRb has no detectable effect on tumorigenesis. In contrast, it significantly delays progression to invasive and lethal prostate cancer. Tumor delay is associated with induction of a senescence response. We conclude that the pRb/E2f interaction is critical for preventing tumor initiation, but that pRb can use additional context-dependent mechanisms to restrain tumor progression.


Assuntos
Progressão da Doença , Fatores de Transcrição E2F/metabolismo , Genes do Retinoblastoma , Neoplasias da Próstata/patologia , Proteína do Retinoblastoma/metabolismo , Alelos , Animais , Análise Mutacional de DNA , Modelos Animais de Doenças , Heterozigoto , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Neoplasias da Próstata/metabolismo
5.
Dev Biol ; 346(1): 11-24, 2010 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-20624380

RESUMO

Fibronectin (Fn) plays an important part in the branching morphogenesis of salivary gland, lung, and kidney. Here, we examine the effect of the conditional knockout of Fn in the mammary epithelium [Fn(MEp-/-)] on postnatal mammary gland development, using Cre-loxP-mediated gene knockout technology. Our data show that Fn deletion causes a moderate retardation in outgrowth and branching of the ductal tree in 5-week-old mice. These defects are partially compensated in virgin 16-week-old mice. However, mammary glands consisting of Fn-deficient epithelial cells fail to undergo normal lobuloalveolar differentiation during pregnancy. The severity of lobuloalveolar impairment ranged from lobular hypoplasia to aplasia in some cases and was associated with the amount of Fn protein recovered from these glands. Decreased rates of mammary epithelial cell proliferation accounted for delayed ductal outgrowth in virgin and lack of alveologenesis in pregnant Fn(MEp-/-) mice. Concomitant decreased expression of integrin beta(1) (Itgb1) and lack of autophosphorylation of focal adhesion kinase (Fak) suggest that this pathology might, at least in part, be mediated by disruption of the Fn/Itgb1/Fak signaling pathway.


Assuntos
Fibronectinas/fisiologia , Glândulas Mamárias Animais/crescimento & desenvolvimento , Animais , Bromodesoxiuridina/metabolismo , Diferenciação Celular , Feminino , Proteína-Tirosina Quinases de Adesão Focal/fisiologia , Hiperplasia , Integrases/fisiologia , Integrina beta1/fisiologia , Queratina-8/análise , Glândulas Mamárias Animais/irrigação sanguínea , Glândulas Mamárias Animais/citologia , Glândulas Mamárias Animais/patologia , Vírus do Tumor Mamário do Camundongo/genética , Camundongos , Morfogênese , Neovascularização Fisiológica , Molécula-1 de Adesão Celular Endotelial a Plaquetas/análise , Gravidez , Recombinação Genética
6.
Int J Oncol ; 36(6): 1419-28, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20428765

RESUMO

Supra-nutritional selenium supplementation has emerged as an attractive new approach to intervene in a range of human cancers, in particular prostate cancer. However, scanty information is currently available on molecular mechanisms underlying selenium's anticancer action. The tumor suppressor p53 plays an important role in preventing transformation by transcriptional regulation of a range of genes that are involved in vital cell functions such as DNA repair, cell cycle arrest, and induction of apoptosis. Here we report that incubation of LNCaP human prostate cancer cells (p53 +/+) with a natural form of selenium triggers rapid transcriptional activation of p53, and up-regulation of the expression of p53-target genes as well as induction of miR-34 class of microRNAs. Moreover, blocking p53 function by transfection of cells with a dominant-negative, mutated p53 gene, or by siRNA, significantly reduced selenium-induced expression of p53-target genes and induction of apoptosis. Since majority of the early-stage human prostate cancers bear functional p53 gene (p53+/+), our findings indicate that the anticancer action of selenium may involve transactivation of p53 as a potential mechanism, and suggest that selenite may be useful not only for prevention but also for treatment of human prostate cancer.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Neoplasias da Próstata/metabolismo , Selenito de Sódio/farmacologia , Proteína Supressora de Tumor p53/efeitos dos fármacos , Apoptose/genética , Western Blotting , Linhagem Celular Tumoral , Humanos , Masculino , Estadiamento de Neoplasias , Neoplasias da Próstata/genética , Neoplasias da Próstata/patologia , Interferência de RNA , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transcrição Gênica/efeitos dos fármacos , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/metabolismo
7.
J Biomed Opt ; 12(6): 064007, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18163823

RESUMO

Progress in biomedical imaging depends on the development of probes that combine low toxicity with high sensitivity, resolution, and stability. Toward that end, a new class of highly fluorescent core-shell silica nanoparticles with narrow size distributions and enhanced photostability, known as C dots, provide an appealing alternative to quantum dots. Here, C dots are evaluated with a particular emphasis on in-vivo applications in cancer biology. It is established that C dots are nontoxic at biologically relevant concentrations, and can be used in a broad range of imaging applications including intravital visualization of capillaries and macrophages, sentinel lymph node mapping, and peptide-mediated multicolor cell labeling for real-time imaging of tumor metastasis and tracking of injected bone marrow cells in mice. These results demonstrate that fluorescent core-shell silica nanoparticles represent a powerful novel imaging tool within the emerging field of nanomedicine.


Assuntos
Corantes Fluorescentes , Nanopartículas , Pontos Quânticos , Dióxido de Silício , Animais , Linhagem Celular Tumoral , Diagnóstico por Imagem/métodos , Feminino , Corantes Fluorescentes/farmacocinética , Corantes Fluorescentes/toxicidade , Masculino , Camundongos , Camundongos Endogâmicos ICR , Camundongos Transgênicos , Microscopia Eletrônica de Varredura , Nanomedicina , Nanopartículas/toxicidade , Nanopartículas/ultraestrutura , Neoplasias da Próstata/patologia , Biópsia de Linfonodo Sentinela , Dióxido de Silício/farmacocinética , Dióxido de Silício/toxicidade , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...